Bupropion (BUP) may be less likely than other antidepressants to cause
switches into mania and rapid cycling, suggesting utility in bipolar
disorder. The combination of BW with the mood-stabilizing anticonvulsa
nts carbamazepine (CBZ) or valproate (VPA) is a strategy that might fu
rther lessen the risk of mania. CBZ induces, and to a lesser extent WA
inhibits the hepatic metabolism of various medications, but their eff
ects on BUP have not been previously studied. Inpatients with mood dis
orders had pharmacokinetic profiles of BUP and metabolites assessed af
ter single, oral, 150-mg doses of BUP while receiving placebo (N = 17)
or during chronic blind CBZ (N = 12) or VPA (N = 5) monotherapy. CBZ
but not VPA therapy decreased BUP peak concentrations (C-max) by 87% (
p < 0.0001) and 24-h area under the curve (AUG) by 90% (p < 0.0001), t
hreohydrobupropion C-max by 81% (p < 0.0009) and AUC by 86% (p < 0.002
), and erythropydrobupropion C-max by 86% (p < 0.05) and AUC by 96% (p
< 0.05). CBZ increased hydroxybupropion (H-BUP) C-max by 71% (p < 0.0
07) and AUC by 50% (p < 0.05). VPA increased H-BW C-max by 56% (p < 0.
09) and H-BUP AUC by 94% (p < 0.02). Thus, CBZ markedly decreased BUP
and increased H-BUP concentrations, whereas VPA did not affect BUP but
increased H-BUP concentrations. Further studies are required to deter
mine how these differential effects of CBZ and VPA on BUP pharmacokine
tics influence the tolerability and efficacy of combination therapies
with these agents.